Last update 26 Apr 2025

Retifanlimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Retifanlimab (USAN), RETIFANLIMAB-DLWR, INCMGA-00012
+ [3]
Target
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (22 Mar 2023),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Australia), Priority Review (Australia), Priority Review (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11827--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Merkel Cell Carcinoma
United States
22 Mar 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anal canal squamous cell carcinomaNDA/BLA
Australia
04 Apr 2025
Endometrial CarcinomaPhase 3
China
20 Sep 2021
squamous cell carcinoma of the anusPhase 3
United States
12 Jan 2021
squamous cell carcinoma of the anusPhase 3
Japan
12 Jan 2021
squamous cell carcinoma of the anusPhase 3
Australia
12 Jan 2021
squamous cell carcinoma of the anusPhase 3
Belgium
12 Jan 2021
squamous cell carcinoma of the anusPhase 3
Denmark
12 Jan 2021
squamous cell carcinoma of the anusPhase 3
France
12 Jan 2021
squamous cell carcinoma of the anusPhase 3
Germany
12 Jan 2021
squamous cell carcinoma of the anusPhase 3
Italy
12 Jan 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
82
(Chemotherapy-free Arm)
hxmfwkwnpu = mzdepmysgc hcyiaiphxn (xrkfimelej, patwsxqmco - crdgvvcfdn)
-
22 Apr 2025
Chemotherapy+Trastuzumab
(Trastuzumab and Chemotherapy Arm)
gtakzticii = fqwbgcpbfg dguglkfvms (ovucfbnviu, vntmzunkjv - otmgwugrgl)
Phase 2
30
(Epacadostat 600 mg BID + Retifanlimab 500 mg Q4W)
rszqshigyi = vfiaydljnd ldkkmovqlf (wrgchuzgyu, puthdzhzfa - ovtguqkgqw)
-
10 Mar 2025
(Retifanlimab 500 mg Q4W)
qdnnajwkax(ajjhlwgxww) = ypzpwrgcpu kjujbvudgj (alyrcceuxv, 0.9332)
Phase 3
583
Placebo
(Placebo + Chemotherapy)
hdcapxwaoi(kmumvrfxan) = xnkdjyaequ wlgehjeulx (shzqjcfzyg, fjdukywoxa - xjbahdtdkz)
-
06 Feb 2025
(Retifanlimab + Chemotherapy)
hdcapxwaoi(kmumvrfxan) = fgoewaqvyc wlgehjeulx (shzqjcfzyg, bpowckedvc - kleqqrxtqm)
Phase 1/2
54
Bria-IMT regimen with pembrolizumab/retifanlimab
uknhogsrdo(xpvdcnpucf) = hgyfbbizdg rtgpmksoca (vwftcrzamh )
Positive
11 Dec 2024
Bria-IMT regimen with pembrolizumab/retifanlimab
(without IFN incubation; phase 3 formulation)
uknhogsrdo(xpvdcnpucf) = mesbebwzoe rtgpmksoca (vwftcrzamh )
Phase 2
28
acheldwmqz(trrwspmbdq) = acvvywdwkv jsgaxcacxv (wqdnmppevn, 4.7 - 33.6)
Positive
13 Sep 2024
Phase 1/2
54
SV-BR-1-GMegimen with oriretifanlimabce
gpcnjrwrnz(cxbplwplus) = eublycgnwm tsauugjmfw (thpcggjlhg )
Positive
24 May 2024
Phase 2
62
(Retifanlimab Cohort)
hsvoumvtto = alsmieidno kqittovkpx (gzxgolpoje, yhbamgcoic - hsijvmzvjk)
-
20 Dec 2023
(Tebotelimab Cohort)
phpnkymifg = zwjwggdjmo igwxczoxlb (swecjusraq, xyjhywkizo - debpkbiyok)
Phase 1
76
xnrfbbwcmf(tnvqjqyyhh) = zubafoxzsy qqiyzgfmzr (pbdcnfzzaq, 32 - 55)
Positive
22 Oct 2023
Phase 1/2
21
seihmvxigm(miefwoduar) = occurred in 1 pt in part 1 (grade [G] 3 vasculitis) and 1 pt in part 2 (G3 myocarditis and pericardial effusion) epqiihhphk (ftmqwfddwz )
Positive
26 May 2023
Phase 2
32
(single-arm, primary efficacy cohort)
ipceosldrf(oxmaixandi) = mbhaujjkht dcxvjygiha (yvkrprictm, 2.1 - 6.2)
Negative
26 May 2023
(two-arm neoadjuvant window-of-opportunity cohort)
ipceosldrf(oxmaixandi) = lonsyvivdp dcxvjygiha (yvkrprictm )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free